SCHEMBL2165356

SCHEMBL2165356

O=C1c2ccc(Cl)c(Cl)c2C(=O)c2c(O)ccc(O)c21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.60
▸ MEN1 O00255 6/20 0.60
▸ KMT2A Q03164 6/20 0.60
▸ MAOA P21397 5/20 0.60
▸ ALDH1A1 P00352 5/20 0.60
▸ TDP1 Q9NUW8 5/20 0.60
▸ MAPK1 P28482 5/20 0.60
▸ HPGD P15428 5/20 0.60
▸ CYP3A4 P08684 4/20 0.60
▸ APEX1 P27695 3/20 0.60
▸ RECQL P46063 3/20 0.60
▸ THRB P10828 3/20 0.60
▸ ALOX15 P16050 3/20 0.60
▸ HSD17B10 Q99714 3/20 0.60
▸ CSNK2A2 P19784 3/20 0.60
▸ CSNK2B P67870 3/20 0.60
▸ CSNK2A1 P68400 3/20 0.60
▸ CSNK2A3 Q8NEV1 3/20 0.60
▸ KDM4E B2RXH2 2/20 0.60
▸ TP53 P04637 2/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10732300 0.85 MEN1 (0.60) MAPTMEN1KMT2AMAOAALDH1A1
SCHEMBL11788768 0.85 MAOA (0.71) MAPTMEN1KMT2AMAOAALDH1A1
SCHEMBL1323063 0.79 CSNK2A2 (0.54) MAPTMEN1KMT2AMAOAALDH1A1
SCHEMBL7742020 0.79 CSNK2A2 (0.54) MAPTMEN1KMT2AMAOAALDH1A1
SCHEMBL30887225 0.79 CSNK2A2 (0.54) MAPTMEN1KMT2AMAOAALDH1A1
SCHEMBL7738621 0.79 CSNK2A2 (0.54) MAPTMEN1KMT2AMAOAALDH1A1
SCHEMBL10356073 0.79 CSNK2A2 (0.54) MAPTMEN1KMT2AMAOAALDH1A1
SCHEMBL497611 0.79 CSNK2A2 (0.54) MAPTMEN1KMT2AMAOAALDH1A1
SCHEMBL6754088 0.78 CYP3A4 (0.68) MAPTALDH1A1TDP1MAPK1HPGD
SCHEMBL10356146 0.78 MAOA (0.57) MAPTMEN1KMT2AMAOAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8277695-B2 Reversibly thermochromic compositions BASF SE (DE) 2012-10-02 — — US disclosed
EP-2032657-B1 REVERSIBLY THERMOCHROMIC COMPOSITIONS BASF SE (DE) 2011-08-10 — — EP disclosed
US-20110180767-A1 Reversibly thermochromic compositions CIBA CORPORATION 2011-07-28 — — US disclosed
EP-2032657-A2 REVERSIBLY THERMOCHROMIC COMPOSITIONS Ciba Holding Inc. (CH) 2009-03-11 — — EP disclosed
WO-2007147847-A2 REVERSIBLY THERMOCHROMIC COMPOSITIONS CIBA HOLDING INC. (CH) 2007-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110180767-A1 Reversibly thermochromic compositions C1R, C3AR1, C9 MAPT 55/4885MEN1 1208/4885KMT2A 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback